Table 2. Adverse events and withdrawal rate of the two treatment groups.
|
Age group (y.o.) |
|||||||
|---|---|---|---|---|---|---|---|
|
65–74 y.o. |
75–84 y.o. |
65–74 vs. 75–84y.o. | |||||
| Olmesartan plus CCB | Olmesartan plus diuretic | P-value | Olmesartan plus CCB | Olmesartan plus diuretic | P-value | P-value | |
| Withdrawal rate | 290 (20.2) | 444 (31.2) | <0.001 | 231 (21.4) | 366 (33.9) | <0.001 | 0.14 |
| Withdrawal due to SAE | 31 (2.1) | 57 (3.9) | 0.007 | 46 (4.2) | 74 (6.6) | 0.011 | <0.001 |
| Withdrawal due to drug-related SAE | 2 (0.1) | 9 (0.6) | 0.065 | 3 (0.3) | 7 (0.6) | 0.34 | 0.83 |
| Any adverse event | 343 (23.5) | 395 (27.1) | 0.03 | 307 (27.7) | 354 (31.7) | 0.037 | <0.001 |
| SAE | 96 (6.6) | 118 (8.1) | 0.14 | 115 (10.4) | 135 (12.1) | 0.2 | <0.001 |
| Drug-related SAE | 3 (0.2) | 13 (0.9) | 0.021 | 6 (0.5) | 9 (0.8) | 0.61 | 0.59 |
Abbreviations: CCB, calcium channel blocker; SAE, serious adverse event; y.o., years old.
Data are n (%).